Depósito Académico >
CIMA (Centro de Investigación Médica Aplicada) >
Área de Ciencias Cardiovasculares >
Aterosclerosis e inflamación >
DA - CIMA - Cardiovasculares - Aterosclerosis e inflamación - Artículos de revista >
|Randomized study of aprotinin and DDAVP to reduce postoperative bleeding after cardiopulmonary bypass surgery|
|Authors: ||Rocha, E. (Eduardo)|
Hidalgo, F. (Francisco)
Llorens, R. (Rafael)
Melero, J.M. (José María)
Arroyo, J.L. (José L.)
Paramo, J.A. (José Antonio)
|Keywords: ||Cardiopulmonary bypass|
|Issue Date: ||1994|
|Publisher: ||Lippincott, Williams & Wilkins|
|Publisher version: ||http://circ.ahajournals.org/content/90/2/921|
|Citation: ||Rocha E, Hidalgo F, Llorens R, Melero JM, Arroyo JL, Paramo JA. Randomized study of aprotinin and DDAVP to reduce postoperative bleeding after cardiopulmonary bypass surgery. Circulation 1994 Aug;90(2):921-927.|
BACKGROUND: Patients on cardiopulmonary bypass (CPB) have an increased susceptibility to postoperative bleeding. Previous reports using desmopressin acetate (DDAVP) for the prevention of postoperative bleeding have given contradictory results, whereas the protease inhibitor aprotinin has been shown to reduce blood loss after this type of surgery. This randomized study was performed to assess the efficacy of DDAVP versus aprotinin in the prevention of bleeding after CPB.
METHODS AND RESULTS: One hundred nine of 122 eligible patients were randomized to four different groups: Group A (n = 28) received aprotinin starting with a bolus of 2 x 10(6) KIU followed by a continuous infusion of 0.5 x 10(6) KIU/h until the end of surgery; group B (n = 25) received of DDAVP 0.3 micrograms/kg i.v. on completion of CPB; group C (n = 28) received two doses of DDAVP, the first as in group B and an additional dose 6 hours after surgery; group D (n = 28) received no treatment. There was a marked reduction of postoperative blood loss either at 12 hours (P < .01) or 72 hours (P < .02) in the aprotinin group compared with all other groups, whereas no significant effect was observed in either of the two DDAVP regimens. A significant reduction in the amount of blood used was observed only in the aprotinin group (P < .01). Of the plasma fibrinolytic components assayed, there was a significant reduction of the fibrin degradation product generation in the aprotinin group (P < .001), whereas a significant systemic hyperfibrinolysis was observed in both DDAVP-treated groups and the control group. No side effects related to the study drugs were observed in any patient.
CONCLUSIONS: Aprotinin inhibited fibrinolysis; this correlated with a significant reduction of postoperative blood loss and need for blood replacement after CPB. Neither one nor two doses of DDAVP had a beneficial effect. Aprotinin offers a better alternative than DDAVP in the prevention of bleeding after CPB.
|Permanent link: ||http://hdl.handle.net/10171/22910|
|Appears in Collections:||DA - Medicina - Cardiología y Cirugía Cardiovascular - Artículos de revista|
DA - Medicina - Anestesiología - Artículos de revista
DA - Medicina - Hematología - Artículos de revista
DA - CUN - Cirugía cardiaca - Artículos de revista
DA - CUN - Anestesia y cuidados intensivos - Artículos de revista
DA - CUN - Hematología y Hemoterapia - Artículos de revista
DA - CIMA - Cardiovasculares - Aterosclerosis e inflamación - Artículos de revista
|Files in This Item:|
| View / Open |
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.